Elan and Transition Achieve Enrollment Target in Phase II Alzheimer's Study
Posted on: Monday, 20 October 2008, 09:00 CDT
Elan, a neuroscience-based biotechnology company, and biopharmaceutical company Transition Therapeutics, have achieved the patient enrollment target for a Phase II clinical study of ELND005 in patients with Alzheimer's disease.
The Phase II clinical study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in patients with mild to moderate Alzheimer's disease. Each patient's planned treatment period is approximately 18 months.
ELND005 is an orally administered therapeutic agent that has received fast track designation from the FDA for treatment of mild to moderate Alzheimer's disease.
Fast track designation facilitates development and may expedite regulatory review of drugs that the FDA recognizes as potentially addressing an unmet medical need for serious or life-threatening conditions.
Source: Datamonitor
Related Articles
- Viral Genetics Reports Initial Findings From Lyme Disease Study
- Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study
- Government Halts Chelation Heart Disease Study
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- Abdominal Fat Distribution Predicts Heart Disease: Study
- New Periodontal Disease Study Shows SRP is Significantly More Effective With Local Antibiotics
- $4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments
- FDA Authorizes Huntington's Disease Study
- Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study; Conference Call Begins at 1:00 P.M. Eastern Time Today
- Green Tea Ingredient Protects Brain Against Alzheimer's Disease: Study
 |
 |
User Comments (0)
RSS Feeds